New insider activity at Tango Therapeutics ( (TNGX) ) has taken place on September 9, 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
In a notable transaction, significant shareholder Third Rock Ventures IV, L.P. has offloaded 729,365 shares of Tango Therapeutics. This sale has a total value of $5,108,148, marking a substantial movement in the company’s stock holdings.
Recent Updates on TNGX stock
In the last 24 hours, Tango Therapeutics (TNGX) has experienced notable developments impacting its stock. Douglas Barry, the Chief Legal and Compliance Officer, announced his resignation, which could influence the company’s strategic direction. Piper Sandler initiated coverage with an Overweight rating and a price target of $11, citing renewed investor confidence in the synthetic lethality space and the potential of Tango’s TNG462, especially after positive competitor data at ASCO. This optimism is based on the anticipated clinical updates in pancreatic cancer and NSCLC, which may demonstrate the drug’s differentiated durability and de-risk its potential as a blockbuster. However, financial challenges such as declining revenues and persistent losses, combined with a negative P/E ratio, have led to a Neutral rating by Spark, TipRanks’ AI Analyst, despite positive technical momentum.
Spark’s Take on TNGX Stock
According to Spark, TipRanks’ AI Analyst, TNGX is a Neutral.
Tango Therapeutics’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. While technical indicators show some positive momentum, the negative valuation metrics and recent executive resignation add to the uncertainty. The company needs to address its financial and operational challenges to improve its stock attractiveness.
To see Spark’s full report on TNGX stock, click here.
More about Tango Therapeutics
YTD Price Performance: 117.57%
Average Trading Volume: 2,065,746
Technical Sentiment Signal: Buy
Current Market Cap: $772.1M